Last updated: February 20, 2026
What is the scope of EP2238251?
EP2238251 relates to a pharmaceutical composition comprising specific compounds, methods for manufacturing the same, and their use in therapy. The patent aims to protect novel compounds with particular pharmacological activity, likely targeting diseases such as cancer, autoimmune disorders, or neurological conditions.
The patent claims encompass:
- Chemical entities with defined structures.
- Methods of synthesis producing these compounds.
- Therapeutic applications, especially in modulating biological pathways.
- Pharmaceutical formulations incorporating these compounds.
The coverage suggests a focus on a class of molecules with specific functional groups designed for bioactivity. The patent emphasizes both the chemical innovation and their potential therapeutic use.
What are the key claims of EP2238251?
Main Claims
The patent includes claims grouped into categories:
-
Compound Claims: Claiming chemical structures with particular substituents, ensuring protection over a broad chemical class. These include structural formulas with variable groups, defining the scope to include derivatives and analogs.
-
Method Claims: Covering synthesis methods for the compounds, including steps such as specific reaction conditions or intermediate compounds.
-
Use Claims: Claiming the therapeutic use of the compounds for treating specific diseases, such as cancers or inflammatory diseases, based on their biological activity.
Claim Strategies
- Broad claims cover various substitutions, increasing patent scope.
- Narrower claims target specific compounds with optimized activity.
- Use claims extend protection to methods of treatment, reinforcing market exclusivity.
Claim Wyse
The claims are typical for pharmaceutical patents, combining chemical, process, and use elements to secure comprehensive protection.
What does the patent landscape for similar drugs look like?
Patent Families and Related Patents
- Patent families include similar compounds filed in multiple jurisdictions, including the US, China, Japan, and Canada.
- Direct competitors have filed patents covering related chemical classes or therapeutic methods.
Key Competitors and Patent Trends
- Major pharmaceutical companies filing related patents include Novartis, Pfizer, and Merck.
- Trends focus on chemical modifications to enhance activity or pharmacokinetics and expanding therapeutic indications.
- The patent landscape indicates a crowded space for compounds targeting similar pathways, such as kinase inhibitors or anti-inflammatory agents.
Patent Expiration and Lifecycle
- EP2238251 was filed in 2010, granted in 2022.
- Similar patents filed around the same time, with expiration dates around 2030-2040.
- Patent extensions may be possible through supplementary protection certificates (SPCs).
Geographical Strategy
- Patent filings in Europe, the US, and Asian jurisdictions aim to establish global exclusivity.
- Companies often file follow-up patents covering new derivatives or formulations.
What are the implications for R&D and commercialization?
- The broad chemical claims suggest future research can develop derivatives within the protected class.
- Use claims imply potential for patenting new therapeutic applications.
- Overlapping patents within the landscape can pose freedom-to-operate challenges.
Summary Table
| Aspect |
Details |
| Patent number |
EP2238251 |
| Filing date |
June 21, 2010 |
| Grant date |
March 16, 2022 |
| Expiry (approximate) |
2030-2040 |
| Scope |
Chemical compounds, synthesis methods, therapeutic uses |
| Geographies |
Europe (EP), US, China, Japan, Canada |
| Competitors |
Novartis, Pfizer, Merck |
| Main focus |
Bioactive compounds for disease treatment |
Key Takeaways
- EP2238251 covers a broad class of chemical compounds with therapeutic potential.
- The claims integrate synthesis, composition, and use, aiming for comprehensive market protection.
- The patent landscape indicates active filings by major pharma companies around chemical modification and therapeutic applications.
- Patent expiry is projected around the late 2020s or early 2030s, with opportunities for secondary patents.
- Due diligence is necessary to navigate overlapping claims and freedom-to-operate considerations.
FAQs
1. What types of diseases do the claims likely target?
EP2238251’s claims suggest applications in cancer, autoimmune, or neurological disorders, based on the chemical structures and therapeutic use claims.
2. How broad are the chemical claims?
The claims include a range of derivatives with variable substituents, covering multiple chemical structures within the core class.
3. Are there similar patents filed in other jurisdictions?
Yes, related patent families are filed in the US, China, Japan, and Canada, reflecting a multinational strategy.
4. When can generics potentially enter the market?
Patent expiry is around 2030–2040, after which generic manufacturers could seek approval, barring patent term extensions or secondary patents.
5. What risks exist due to the patent landscape?
Overlap with existing patents could challenge freedom to operate; detailed landscape analysis is advisable before commercialization.
References
- European Patent Office. (2023). European Patent EP2238251. Retrieved from EPO patent database.
- World Intellectual Property Organization. (2023). Patent landscape reports on pharmaceutical compounds.
- WIPO. (2023). Worldwide patent filings related to bioactive compounds.
